WallStreetZenWallStreetZen

NASDAQ: IBRX
Immunitybio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IBRX

Based on 7 analysts offering 12 month price targets for Immunitybio Inc

Min Forecast
$7.00-4.11%
Avg Forecast
$12.57+72.21%
Max Forecast
$23.00+215.07%

Should I buy or sell IBRX stock?

Based on 7 analysts offering ratings for Immunitybio Inc.

Strong Buy
Strong Buy
6 analysts 85.71%
Buy
1 analysts 14.29%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IBRX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates IBRX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their IBRX stock forecasts and price targets.

IBRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-26
lockedlocked$00.00+00.00%2026-03-12
lockedlocked$00.00+00.00%2026-03-04Find Out Why
lockedlocked$00.00+00.00%2026-02-23Find Out Why
lockedlocked$00.00+00.00%2026-01-23
Piper Sandler
Top 30%
71
Strong BuyMaintains$7.00-4.11%2026-01-20Find out why
Jefferies
Top 17%
84
Strong BuyMaintains$9.00+23.29%2025-12-12Find out why

1 of 1

Forecast return on equity

Is IBRX forecast to generate an efficient return?

Company
-256.68%
Industry
69.51%
Market
178.05%
IBRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IBRX forecast to generate an efficient return on assets?

Company
255.95%
Industry
31.92%
IBRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IBRX earnings per share forecast

What is IBRX's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.30
Avg 2 year Forecast
-$0.07
Avg 3 year Forecast
$0.45

IBRX revenue forecast

What is IBRX's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$213.7M+88.59%
Avg 2 year Forecast
$493.9M+335.93%
Avg 3 year Forecast
$1.2B+989.26%
IBRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IBRX revenue growth forecast

How is IBRX forecast to perform vs Biotechnology companies and vs the US market?

Company
115.48%
Industry
38.7%
Market
13.79%
IBRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IBRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IBRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IBRX$7.30$12.57+72.21%Strong Buy
HALO$64.49$78.56+21.81%Buy
KRYS$260.95$326.25+25.02%Strong Buy
KYMR$85.40$119.57+40.01%Strong Buy
CYTK$66.73$92.23+38.22%Strong Buy
View Top Biotech Stocks

Immunitybio Stock Forecast FAQ

Is Immunitybio Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: IBRX) stock is to Strong Buy IBRX stock.

Out of 7 analysts, 6 (85.71%) are recommending IBRX as a Strong Buy, 1 (14.29%) are recommending IBRX as a Buy, 0 (0%) are recommending IBRX as a Hold, 0 (0%) are recommending IBRX as a Sell, and 0 (0%) are recommending IBRX as a Strong Sell.

If you're new to stock investing, here's how to buy Immunitybio stock.

What is IBRX's earnings growth forecast for 2026-2028?

(NASDAQ: IBRX) Immunitybio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.03%.

Immunitybio's earnings in 2026 is -$351,398,000.On average, 7 Wall Street analysts forecast IBRX's earnings for 2026 to be -$312,545,883, with the lowest IBRX earnings forecast at -$372,793,214, and the highest IBRX earnings forecast at -$259,084,087. On average, 6 Wall Street analysts forecast IBRX's earnings for 2027 to be -$70,836,879, with the lowest IBRX earnings forecast at -$251,887,307, and the highest IBRX earnings forecast at $161,927,554.

In 2028, IBRX is forecast to generate $457,920,843 in earnings, with the lowest earnings forecast at $191,434,353 and the highest earnings forecast at $647,710,217.

What is IBRX's revenue growth forecast for 2026-2028?

(NASDAQ: IBRX) Immunitybio's forecast annual revenue growth rate of 115.48% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.

Immunitybio's revenue in 2026 is $113,288,000.On average, 7 Wall Street analysts forecast IBRX's revenue for 2026 to be $219,656,012,574, with the lowest IBRX revenue forecast at $173,699,430,491, and the highest IBRX revenue forecast at $276,469,451,633. On average, 7 Wall Street analysts forecast IBRX's revenue for 2027 to be $507,743,123,660, with the lowest IBRX revenue forecast at $285,342,053,498, and the highest IBRX revenue forecast at $843,740,228,596.

In 2028, IBRX is forecast to generate $1,268,689,536,704 in revenue, with the lowest revenue forecast at $841,005,452,123 and the highest revenue forecast at $1,554,504,521,472.

What is IBRX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: IBRX) forecast ROA is 255.95%, which is higher than the forecast US Biotechnology industry average of 31.92%.

What is IBRX's Price Target?

According to 7 Wall Street analysts that have issued a 1 year IBRX price target, the average IBRX price target is $12.57, with the highest IBRX stock price forecast at $23.00 and the lowest IBRX stock price forecast at $7.00.

On average, Wall Street analysts predict that Immunitybio's share price could reach $12.57 by Mar 26, 2027. The average Immunitybio stock price prediction forecasts a potential upside of 72.21% from the current IBRX share price of $7.30.

What is IBRX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: IBRX) Immunitybio's current Earnings Per Share (EPS) is -$0.38. On average, analysts forecast that IBRX's EPS will be -$0.30 for 2026, with the lowest EPS forecast at -$0.36, and the highest EPS forecast at -$0.25. On average, analysts forecast that IBRX's EPS will be -$0.07 for 2027, with the lowest EPS forecast at -$0.25, and the highest EPS forecast at $0.16. In 2028, IBRX's EPS is forecast to hit $0.45 (min: $0.19, max: $0.63).

What is IBRX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: IBRX) forecast ROE is -256.68%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.